FRACTYL HEALTH INC (GUTS) Stock Price & Overview
NASDAQ:GUTS • US35168W1036
Current stock price
The current stock price of GUTS is 0.4504 USD. Today GUTS is down by -1.44%. In the past month the price decreased by -7.89%. In the past year, price decreased by -55.41%.
GUTS Key Statistics
- Market Cap
- 69.078M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.84
- Dividend Yield
- N/A
GUTS Stock Performance
GUTS Stock Chart
GUTS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GUTS. When comparing the yearly performance of all stocks, GUTS is a bad performer in the overall market: 97.55% of all stocks are doing better.
GUTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GUTS. GUTS has a bad profitability rating. Also its financial health evaluation is rather negative.
GUTS Earnings
GUTS Forecast & Estimates
11 analysts have analysed GUTS and the average price target is 5.34 USD. This implies a price increase of 1086.68% is expected in the next year compared to the current price of 0.4504.
GUTS Groups
Sector & Classification
GUTS Financial Highlights
Over the last trailing twelve months GUTS reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS decreased by -20.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -106.94% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GUTS Ownership
GUTS Latest News, Press Relases and Analysis
GUTS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 17.73 | 177.764B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.32 | 160.743B | ||
| SYK | STRYKER CORP | 21.96 | 127.168B | ||
| BSX | BOSTON SCIENTIFIC CORP | 17.69 | 92.877B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.83 | 47.155B | ||
| IDXX | IDEXX LABORATORIES INC | 38.78 | 45.976B | ||
| BDX | BECTON DICKINSON AND CO | 11.37 | 44.226B | ||
| RMD | RESMED INC | 18.41 | 32.768B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.49 | 32.085B | ||
| DXCM | DEXCOM INC | 24.82 | 24.327B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.78 | 17.804B | ||
| HOLX | HOLOGIC INC | 15.48 | 16.969B | ||
| PODD | INSULET CORP | 31.32 | 14.326B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GUTS
Company Profile
Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
Company Info
IPO: 2024-02-02
FRACTYL HEALTH INC
3 Van De Graaff Drive, Suite 200
Burlington MASSACHUSETTS US
Employees: 107
Phone: 17819028800
FRACTYL HEALTH INC / GUTS FAQ
What does GUTS do?
Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
What is the current price of GUTS stock?
The current stock price of GUTS is 0.4504 USD. The price decreased by -1.44% in the last trading session.
Does FRACTYL HEALTH INC pay dividends?
GUTS does not pay a dividend.
What is the ChartMill rating of FRACTYL HEALTH INC stock?
GUTS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about FRACTYL HEALTH INC (GUTS) stock?
11 analysts have analysed GUTS and the average price target is 5.34 USD. This implies a price increase of 1086.68% is expected in the next year compared to the current price of 0.4504.
Would investing in FRACTYL HEALTH INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GUTS.
What is the employee count for GUTS stock?
FRACTYL HEALTH INC (GUTS) currently has 107 employees.